1887

Abstract

Irritable bowel syndrome (IBS) is a functional gastrointestinal disorder that has been associated with aberrant microbiota. This review focuses on the recent molecular insights generated by analysing the intestinal microbiota in subjects suffering from IBS. Special emphasis is given to studies that compare and contrast the microbiota of healthy subjects with that of IBS patients classified into different subgroups based on their predominant bowel pattern as defined by the Rome criteria. The current data available from a limited number of patients do not reveal pronounced and reproducible IBS-related deviations of entire phylogenetic or functional microbial groups, but rather support the concept that IBS patients have alterations in the proportions of commensals with interrelated changes in the metabolic output and overall microbial ecology. The lack of apparent similarities in the taxonomy of microbiota in IBS patients may partially arise from the fact that the applied molecular methods, the nature and location of IBS subjects, and the statistical power of the studies have varied considerably. Most recent advances, especially the finding that several uncharacterized phylotypes show non-random segregation between healthy and IBS subjects, indicate the possibility of discovering bacteria specific for IBS. Moreover, tools are being developed for the functional analysis of the relationship between the intestinal microbiota and IBS. These approaches may be instrumental in the evaluation of the ecological dysbiosis hypothesis in the gut ecosystem. Finally, we discuss the future outlook for research avenues and candidate microbial biomarkers that may eventually be used in IBS diagnosis.

Loading

Article metrics loading...

/content/journal/micro/10.1099/mic.0.043257-0
2010-11-01
2024-03-28
Loading full text...

Full text loading...

/deliver/fulltext/micro/156/11/3205.html?itemId=/content/journal/micro/10.1099/mic.0.043257-0&mimeType=html&fmt=ahah

References

  1. Aerssens J., Camilleri M., Talloen W., Thielemans L., Göhlmann H. W., Van Den Wyngaert I., Thielemans T., De Hoogt R., Andrews C. N. other authors 2008; Alterations in mucosal immunity identified in the colon of patients with irritable bowel syndrome. Clin Gastroenterol Hepatol 6:194–205
    [Google Scholar]
  2. Bocci V. 1992; The neglected organ: bacterial flora has a crucial immunostimulatory role. Perspect Biol Med 35:251–260
    [Google Scholar]
  3. Bourdu S., Dapoigny M., Chapuy E., Artigue F., Vasson M. P., Dechelotte P., Bommelaer G., Eschalier A., Ardid D. 2005; Rectal instillation of butyrate provides a novel clinically relevant model of noninflammatory colonic hypersensitivity in rats. Gastroenterology 128:1996–2008
    [Google Scholar]
  4. Carroll I. M., Shen X. J., Keku T. O., Sartor R. B., Ringel Y. 2008; Characterization of the fecal microbiota in patients with diarrhea predominant irritable bowel syndrome. Gastroenterology 134 (Suppl. 1):A681
    [Google Scholar]
  5. Carroll I. M., Keku T. O., Ringel-Kulka T., Sartor R. B., Ringel Y. 2010; Molecular characterization of the fecal and mucosal-associated intestinal microbiota in patients with diarrhea-predominant IBS and healthy subjects. Gastroenterology 138 (Suppl. 1):S624
    [Google Scholar]
  6. Chadwick V. S., Chen W., Shu D., Paulus B., Bethwaite P., Tie A., Wilson I. 2002; Activation of the mucosal immune system in irritable bowel syndrome. Gastroenterology 122:1778–1783
    [Google Scholar]
  7. Chassard C., Dapoigny M. C., Scott K., Del'Homme C., Dubray C., Eschalier A., Flint H. J., Bernalier-Donadille A. 2009; The intestinal microbiota of irritable bowel syndrome patients is characterized by functional dysbiosis. Gastroenterology 136 (Suppl. 1):A214
    [Google Scholar]
  8. Codling C., O'Mahony L., Shanahan F., Quigley E. M., Marchesi J. R. 2010; A molecular analysis of fecal and mucosal bacterial communities in irritable bowel syndrome. Dig Dis Sci 55:392–397
    [Google Scholar]
  9. Drossman D. A., Corazziari E., Talley N. J., Thompson W. G., Whitehead W. E. 2000; The functional GI disorders and the Rome II process. In Rome II. The Functional Gastrointestinal Disorders, 2nd edn. pp 1–30 Edited by Drossman D. A. McLean, VA: Degnon Associates;
    [Google Scholar]
  10. Duck L. W., Walter M. R., Novak J., Kelly D., Tomasi M., Cong Y., Elson C. O. 2007; Isolation of flagellated bacteria implicated in Crohn's disease. Inflamm Bowel Dis 13:1191–1201
    [Google Scholar]
  11. Duncan S. H., Louis P., Thomson J. M., Flint H. J. 2009; The role of pH in determining the species composition of the human colonic microbiota. Environ Microbiol 11:2112–2122
    [Google Scholar]
  12. Engelbrektson A., Korzenik J. R., Pittler A., Sanders M. E., Klaenhammer T. R., Leyer G., Kitts C. L. 2009; Probiotics to minimize the disruption of faecal microbiota in healthy subjects undergoing antibiotic therapy. J Med Microbiol 58:663–670
    [Google Scholar]
  13. Fleissner C. K., Huebel N., Abd El-Bary M. M., Loh G., Klaus S., Blaut M. 2010; Absence of intestinal microbiota does not protect mice from diet-induced obesity. Br J Nutr 5:1–11
    [Google Scholar]
  14. Frank D. N., St Amand A. L., Feldman R. A., Boedeker E. C., Harpaz N., Pace N. R. 2007; Molecular-phylogenetic characterization of microbial community imbalances in human inflammatory bowel diseases. Proc Natl Acad Sci U S A 104:13780–13785
    [Google Scholar]
  15. Karantanos T., Markoutsaki T., Gazouli M., Anagnou N. P., Karamanolis D. G. 2010; Current insights in to the pathophysiology of irritable bowel syndrome. Gut Pathog 2:3
    [Google Scholar]
  16. Kassinen A., Krogius-Kurikka L., Makivuokko H., Rinttilä T., Paulin L., Corander J., Malinen E., Apajalahti J., Palva A. 2007; The fecal microbiota of irritable bowel syndrome patients differs significantly from that of healthy subjects. Gastroenterology 133:24–33
    [Google Scholar]
  17. Kerckhoffs A. P., Samsom M., van der Rest M. E., de Vogel J., Knol J., Ben-Amor K., Akkermans L. M. 2009; Lower bifidobacteria counts in both duodenal mucosa-associated and fecal microbiota in irritable bowel syndrome patients. World J Gastroenterol 15:2887–2892
    [Google Scholar]
  18. Khoruts A., Dicksved J., Jansson J. K., Sadowsky M. J. 2010; Changes in the composition of the human fecal microbiome after bacteriotherapy for recurrent Clostridium difficile-associated diarrhea. J Clin Gastroenterol 44:354–360
    [Google Scholar]
  19. King T. S., Elia M., Hunter J. O. 1998; Abnormal colonic fermentation in irritable bowel syndrome. Lancet 352:1187–1189
    [Google Scholar]
  20. Krogius-Kurikka L., Lyra A., Malinen E., Aarnikunnas J., Tuimala J., Paulin L., Mäkivuokko H., Kajander K., Palva A. 2009; Microbial community analysis reveals high level phylogenetic alterations in the overall gastrointestinal microbiota of diarrhoea-predominant irritable bowel syndrome sufferers. BMC Gastroenterol 9:95
    [Google Scholar]
  21. Lee K. J., Tack J. 2010; Altered intestinal microbiota in irritable bowel syndrome. Neurogastroenterol Motil 22:493–498
    [Google Scholar]
  22. Liu C., Finegold S. M., Song Y., Lawson P. A. 2008; Reclassification of Clostridium coccoides, Ruminococcus hansenii, Ruminococcus hydrogenotrophicus, Ruminococcus luti, Ruminococcus productus and Ruminococcus schinkii as Blautia coccoides gen. nov., comb. nov., Blautia hansenii comb. nov., Blautia hydrogenotrophica comb. nov., Blautia luti comb. nov., Blautia producta comb. nov., Blautia schinkii comb. nov. and description of Blautia wexlerae sp. nov., isolated from human faeces. . Int J Syst Evol Microbiol 58:1896–1902
    [Google Scholar]
  23. Longstreth G. F., Thompson W. G., Chey W. D., Houghton L. A., Mearin F., Spiller R. C. 2006; Functional bowel disorders. Gastroenterology 130:1480–1491
    [Google Scholar]
  24. Louis P., Scott K. P., Duncan S. H., Flint H. J. 2007; Understanding the effects of diet on bacterial metabolism in the large intestine. J Appl Microbiol 102:1197–1208
    [Google Scholar]
  25. Louis P., Young P., Holtrop G., Flint H. J. 2010; Diversity of human colonic butyrate-producing bacteria revealed by analysis of the butyryl-CoA : acetate CoA-transferase gene. Environ Microbiol 12:304–314
    [Google Scholar]
  26. Lyra A., Rinttilä T., Nikkilä J., Krogius-Kurikka L., Kajander K., Malinen E., Mättö J., Mäkelä L., Palva A. 2009; Diarrhoea-predominant irritable bowel syndrome distinguishable by 16S rRNA gene phylotype quantification. World J Gastroenterol 15:5936–5945
    [Google Scholar]
  27. Macsharry J., O'Mahony L., Fanning A., Bairead E., Sherlock G., Tiesman J., Fulmer A., Kiely B., Dinan T. G. other authors 2008; Alterations in mucosal immunity identified in the colon of patients with irritable bowel syndrome. Scand J Gastroenterol 43:1467–1476
    [Google Scholar]
  28. Malinen E., Rinttilä T., Kajander K., Mättö J., Kassinen A., Krogius L., Saarela M., Korpela R., Palva A. 2005; Analysis of the fecal microbiota of irritable bowel syndrome patients and healthy controls with real-time PCR. Am J Gastroenterol 100:373–382
    [Google Scholar]
  29. Malinen E., Krogius-Kurikka L., Lyra A., Nikkilä J., Jääskeläinen A., Rinttilä T., Vilpponen-Salmela T., von Wright A., Palva A. 2010; Association of symptoms with gastrointestinal microbiota in irritable bowel syndrome. WJG (in press)
    [Google Scholar]
  30. Marsh P. D. 2003; Are dental diseases examples of ecological catastrophes?. Microbiology 149:279–294
    [Google Scholar]
  31. Mättö J., Maunuksela L., Kajander K., Palva A., Korpela R., Kassinen A., Saarela M. 2005; Composition and temporal stability of gastrointestinal microbiota in irritable bowel syndrome – a longitudinal study in IBS and control subjects. FEMS Immunol Med Microbiol 43:213–222
    [Google Scholar]
  32. Maukonen J., Satokari R., Mättö J., Söderlund H., Mattila-Sandholm T., Saarela M. 2006; Prevalence and temporal stability of selected clostridial groups in irritable bowel syndrome in relation to predominant faecal bacteria. J Med Microbiol 55:625–633
    [Google Scholar]
  33. Moayyedi P., Ford A. C., Talley N. J., Cremonini F., Foxx-Orenstein A. E., Brandt L. J., Quigley E. M. M. 2010; The efficacy of probiotics in the treatment of irritable bowel syndrome: a systematic review. Gut 59:325–332
    [Google Scholar]
  34. Nakamura N., Lin H. C., McSweeney C. S., Mackie R. I., Gaskins H. R. 2010; Mechanisms of microbial hydrogen disposal in the human colon and implications for health and disease. Annu Rev Food Sci Technol 1:363–395
    [Google Scholar]
  35. Parkes G. C., Brostoff J., Whelan K., Sanderson J. D. 2008; Gastrointestinal microbiota in irritable bowel syndrome: their role in its pathogenesis and treatment. Am J Gastroenterol 103:1557–1567
    [Google Scholar]
  36. Parkes G. C., Sanderson J. D., Whelan K. 2010; Treating irritable bowel syndrome with probiotics: the evidence. Proc Nutr Soc 69:187–194
    [Google Scholar]
  37. Pimentel M., Lezcano S. 2007; Irritable bowel syndrome: bacterial overgrowth – what's known and what to do. Curr Treat Options Gastroenterol 10:328–337
    [Google Scholar]
  38. Pimentel M., Lin H. C., Enayati P., van den Burg B., Lee H. R., Chen J. H., Park S., Kong Y., Conklin J. 2006; Methane, a gas produced by enteric bacteria, slows intestinal transit and augments small intestinal contractile activity. Am J Physiol Gastrointest Liver Physiol 290:G1089–G1095
    [Google Scholar]
  39. Qin J., Li R., Raes J., Arumugam M., Burgdorf K. S., Manichanh C., Nielsen T., Pons N., Levenez F. other authors 2010; A human gut microbial gene catalogue established by metagenomic sequencing. Nature 464:59–65
    [Google Scholar]
  40. Quigley E. M. M. 2009; Review: do patients with functional gastrointestinal disorders have an altered gut flora?. Therapeutic Advances in Gastroenterology 2 (Suppl. 4):s23–s30
    [Google Scholar]
  41. Rajilić-Stojanović M. 2007; Diversity of the human gastrointestinal microbiota – novel perspectives from high throughput analyses. PhD thesis University of Wageningen; The Netherlands:
  42. Rana S. V., Sharma S., Sinha S. K., Kaur H., Sikander A., Singh K. 2009; Incidence of predominant methanogenic flora in irritable bowel syndrome patients and apparently healthy controls from north India. Dig Dis Sci 54:132–135
    [Google Scholar]
  43. Ringel Y., Carroll I. M. 2009; Alterations in the intestinal microbiota and functional bowel symptoms. Gastrointest Endosc Clin N Am 19:141–150
    [Google Scholar]
  44. Scanlan P. D., Shanahan F., Marchesi J. R. 2008; Human methanogen diversity and incidence in healthy and diseased colonic groups using mcrA gene analysis. BMC Microbiol 8:79
    [Google Scholar]
  45. Schoepfer A. M., Schaffer T., Seibold-Schmid B., Muller S., Seibold F. 2008; Antibodies to flagellin indicate reactivity to bacterial antigens in IBS patients. Neurogastroenterol Motil 20:1110–1118
    [Google Scholar]
  46. Serra J., Villoria A., Azpiroz F., Lobo B., Santos J., Accarino A., Malagelada J. R. 2010; Impaired intestinal gas propulsion in manometrically proven dysmotility and in irritable bowel syndrome. Neurogastroenterol Motil 22:401–406
    [Google Scholar]
  47. Sokol H., Seksik P., Furet J. P., Firmesse O., Nion-Larmurier I., Beaugerie L., Cosnes J., Corthier G., Marteau P., Doré J. 2009; Low counts of Faecalibacterium prausnitzii in colitis microbiota. Inflamm Bowel Dis 15:1183–1189
    [Google Scholar]
  48. Spiller R., Garsed K. 2009; Postinfectious irritable bowel syndrome. Gastroenterology 136:1979–1988
    [Google Scholar]
  49. Swidsinski A., Weber J., Loening-Baucke V., Hale L. P., Lochs H. 2005; Spatial organization and composition of the mucosal flora in patients with inflammatory bowel disease. J Clin Microbiol 43:3380–3389
    [Google Scholar]
  50. Tana C., Umesaki Y., Imaoka A., Handa T., Kanazawa M., Fukudo S. 2010; Altered profiles of intestinal microbiota and organic acids may be the origin of symptoms in irritable bowel syndrome. Neurogastroenterol Motil 22:512–519
    [Google Scholar]
  51. Tap J., Mondot S., Levenez F., Pelletier E., Caron C., Furet J. P., Ugarte E., Munoz-Tamayo R., Paslier D. L. other authors 2009; Towards the human intestinal microbiota phylogenetic core. Environ Microbiol 11:2574–2584
    [Google Scholar]
  52. Thompson W. G., Longstreth G. F., Drossman D. A., Heaton K. W., Irvine E. J., Muller-Lissner S. A. 1999; Functional bowel disorders and functional abdominal pain. Gut 45 (Suppl. 2):II43–II47
    [Google Scholar]
  53. Treem W. R., Ahsan N., Kastoff G., Hyams J. S. 1996; Fecal short-chain fatty acids in patients with diarrhea-predominant irritable bowel syndrome: in vitro studies of carbohydrate fermentation. J Pediatr Gastroenterol Nutr 23:280–286
    [Google Scholar]
  54. Turnbaugh P. J., Hamady M., Yatsunenko T., Cantarel B. L., Duncan A., Ley R. E., Sogin M. L., Jones W. J., Roe B. A. other authors 2009; A core gut microbiome in obese and lean twins. Nature 457:480–484
    [Google Scholar]
  55. Vanhoutvin S. A., Troost F. J., Kilkens T. O., Lindsey P. J., Hamer H. M., Jonkers D. M., Venema K., Brummer R. J. 2009; The effects of butyrate enemas on visceral perception in healthy volunteers. Neurogastroenterol Motil 21:952–e76
    [Google Scholar]
  56. Woese C. R. 1987; Bacterial evolution. Microbiol Rev 51:221–271
    [Google Scholar]
  57. Zhang H., Dibaise J. K., Zuccolo A., Kudrna D., Braidotti M., Yu Y., Parameswaran P., Crowell M. D., Wing R. other authors 2009; Human gut microbiota in obesity and after gastric bypass. Proc Natl Acad Sci U S A 106:2365–2370
    [Google Scholar]
  58. Zoetendal E. G., Rajilić-Stojanović M., de Vos W. M. 2008; High-throughput diversity and functionality analysis of the gastrointestinal tract microbiota. Gut 57:1605–1615
    [Google Scholar]
http://instance.metastore.ingenta.com/content/journal/micro/10.1099/mic.0.043257-0
Loading
/content/journal/micro/10.1099/mic.0.043257-0
Loading

Data & Media loading...

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error